Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085835275> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2085835275 endingPage "1041" @default.
- W2085835275 startingPage "1035" @default.
- W2085835275 abstract "Gemcitabine (2',2'-difluorodeoxycytidine) is a novel purine analog with clinical activity against ovarian cancer. Accumulation of gemcitabine triphosphate (dFdCTP) increases in a linear fashion with prolonged infusions of gemcitabine, and there is a strong relationship between intracellular accumulation of dFdCTP and DNA damage. Women with ovarian, fallopian tube, or primary peritoneal carcinoma and documented recurrent disease were eligible for the study. Patients could not have received more than four prior lines of chemotherapy and had to have measurable or evaluable disease. Gemcitabine 800 mg/m2 administered by intravenous infusion at 10 mg/m2/min (fixed dose rate [FDR]) on days 1 and 8 of a 21-day schedule. Twenty-eight patients with a median age 60 (range, 40-77) years were treated. Although 43% were Eastern Cooperative Oncology Group 0, 50% had liver metastases. Eighty-eight cycles of therapy were delivered (median 2 [range, 1-6]). Five of the first ten patients treated at 800 mg/m2 could not receive day 8 FDR-gemcitabine because of neutropenia, and the starting dose was reduced to 700 mg/m2. Even at this dose there was cumulative hematologic toxicity resulting in dose reductions. Vomiting, mucositis, diarrhea, allergy, rash, fever, and alopecia were mild. In 28 patients, there was only one partial response (4%, 95% CI 0-18%) and median time to progression was 1.7 (interquartile range, 1.2-3.9) months. FDR-gemcitabine 700 mg/m2 administered by intravenous infusion at an FDR of 10 mg/m2/min had minimal activity against heavily pretreated recurrent tumors of müllerian origin. The optimal dose and schedule of gemcitabine is yet to be defined in this population." @default.
- W2085835275 created "2016-06-24" @default.
- W2085835275 creator A5000311133 @default.
- W2085835275 creator A5007345034 @default.
- W2085835275 creator A5013091949 @default.
- W2085835275 creator A5030257115 @default.
- W2085835275 creator A5033018791 @default.
- W2085835275 creator A5036620143 @default.
- W2085835275 creator A5037937774 @default.
- W2085835275 creator A5057994626 @default.
- W2085835275 creator A5058249824 @default.
- W2085835275 creator A5089632732 @default.
- W2085835275 creator A5089955620 @default.
- W2085835275 date "2005-11-01" @default.
- W2085835275 modified "2023-09-25" @default.
- W2085835275 title "A phase II study of fixed dose rate gemcitabine in patients with relapsed mullerian tumors" @default.
- W2085835275 cites W1890647543 @default.
- W2085835275 cites W1924785021 @default.
- W2085835275 cites W1985953095 @default.
- W2085835275 cites W2004869577 @default.
- W2085835275 cites W2051000943 @default.
- W2085835275 cites W2052846363 @default.
- W2085835275 cites W2078646154 @default.
- W2085835275 cites W2119148287 @default.
- W2085835275 cites W2138178697 @default.
- W2085835275 cites W2151037883 @default.
- W2085835275 cites W2154737435 @default.
- W2085835275 cites W2239815468 @default.
- W2085835275 cites W2325101513 @default.
- W2085835275 cites W2338170390 @default.
- W2085835275 cites W2990049365 @default.
- W2085835275 doi "https://doi.org/10.1111/j.1525-1438.2005.00482.x" @default.
- W2085835275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16343179" @default.
- W2085835275 hasPublicationYear "2005" @default.
- W2085835275 type Work @default.
- W2085835275 sameAs 2085835275 @default.
- W2085835275 citedByCount "5" @default.
- W2085835275 countsByYear W20858352752013 @default.
- W2085835275 crossrefType "journal-article" @default.
- W2085835275 hasAuthorship W2085835275A5000311133 @default.
- W2085835275 hasAuthorship W2085835275A5007345034 @default.
- W2085835275 hasAuthorship W2085835275A5013091949 @default.
- W2085835275 hasAuthorship W2085835275A5030257115 @default.
- W2085835275 hasAuthorship W2085835275A5033018791 @default.
- W2085835275 hasAuthorship W2085835275A5036620143 @default.
- W2085835275 hasAuthorship W2085835275A5037937774 @default.
- W2085835275 hasAuthorship W2085835275A5057994626 @default.
- W2085835275 hasAuthorship W2085835275A5058249824 @default.
- W2085835275 hasAuthorship W2085835275A5089632732 @default.
- W2085835275 hasAuthorship W2085835275A5089955620 @default.
- W2085835275 hasConcept C121608353 @default.
- W2085835275 hasConcept C126322002 @default.
- W2085835275 hasConcept C126894567 @default.
- W2085835275 hasConcept C143998085 @default.
- W2085835275 hasConcept C2776694085 @default.
- W2085835275 hasConcept C2777063308 @default.
- W2085835275 hasConcept C2777249960 @default.
- W2085835275 hasConcept C2778496288 @default.
- W2085835275 hasConcept C2778570526 @default.
- W2085835275 hasConcept C2780258809 @default.
- W2085835275 hasConcept C2780427987 @default.
- W2085835275 hasConcept C31760486 @default.
- W2085835275 hasConcept C71924100 @default.
- W2085835275 hasConcept C90924648 @default.
- W2085835275 hasConceptScore W2085835275C121608353 @default.
- W2085835275 hasConceptScore W2085835275C126322002 @default.
- W2085835275 hasConceptScore W2085835275C126894567 @default.
- W2085835275 hasConceptScore W2085835275C143998085 @default.
- W2085835275 hasConceptScore W2085835275C2776694085 @default.
- W2085835275 hasConceptScore W2085835275C2777063308 @default.
- W2085835275 hasConceptScore W2085835275C2777249960 @default.
- W2085835275 hasConceptScore W2085835275C2778496288 @default.
- W2085835275 hasConceptScore W2085835275C2778570526 @default.
- W2085835275 hasConceptScore W2085835275C2780258809 @default.
- W2085835275 hasConceptScore W2085835275C2780427987 @default.
- W2085835275 hasConceptScore W2085835275C31760486 @default.
- W2085835275 hasConceptScore W2085835275C71924100 @default.
- W2085835275 hasConceptScore W2085835275C90924648 @default.
- W2085835275 hasIssue "6" @default.
- W2085835275 hasLocation W20858352751 @default.
- W2085835275 hasLocation W20858352752 @default.
- W2085835275 hasOpenAccess W2085835275 @default.
- W2085835275 hasPrimaryLocation W20858352751 @default.
- W2085835275 hasRelatedWork W1936678075 @default.
- W2085835275 hasRelatedWork W1959900711 @default.
- W2085835275 hasRelatedWork W2029599603 @default.
- W2085835275 hasRelatedWork W2044467273 @default.
- W2085835275 hasRelatedWork W2085835275 @default.
- W2085835275 hasRelatedWork W2100029565 @default.
- W2085835275 hasRelatedWork W2166682482 @default.
- W2085835275 hasRelatedWork W2211886307 @default.
- W2085835275 hasRelatedWork W2243375749 @default.
- W2085835275 hasRelatedWork W2246142452 @default.
- W2085835275 hasVolume "15" @default.
- W2085835275 isParatext "false" @default.
- W2085835275 isRetracted "false" @default.
- W2085835275 magId "2085835275" @default.
- W2085835275 workType "article" @default.